MedTrace Logo

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2018-10-23

Study results available
· View outcomes & findings →

Summary

This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).

Conditions

Interventions

BEHAVIORAL

APOE genotype and Alzheimer's disease risk disclosure

Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

BEHAVIORAL

Alzheimer's disease risk disclosure

Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Sponsors & Collaborators

Principal Investigators

  • Robert C Green, MD, MPH · Brigham and Women's Hospital/Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01434667 on ClinicalTrials.gov